Radionuclide Therapy for Neuroendocrine Tumors

被引：110

作者：

Cives, Mauro ^{[1
]}

Strosberg, Jonathan ^{[1
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA

来源：

CURRENT ONCOLOGY REPORTS | 2017年 / 19卷 / 02期

关键词：

Carcinoid tumors; PRRT; Radiolabeled somatostatin analogs; Lutetium; NETTER-1; RADIOLABELED SOMATOSTATIN ANALOG; RECEPTOR CHEMORADIONUCLIDE THERAPY; PHASE I-II; RADIOPEPTIDE LU-177-OCTREOTATE; LU-177-DOTATATE; Y-90-DOTATOC; SURVIVAL; COMBINATION; CAPECITABINE; EXPERIENCE;

D O I：

10.1007/s11912-017-0567-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Peptide receptor radionuclide therapy (PRRT) is a form of systemic radiotherapy that allows targeted delivery of radionuclides to tumor cells expressing high levels of somatostatin receptors. The two radiopeptides most commonly used for PRRT, Y-90-DOTATOC and Lu-177-DOTATATE, have been successfully employed for more than a decade for the treatment of advanced neuroendocrine tumors (NETs). Recently, the phase III, randomized NETTER-1 trial has compared Lu-177-DOTATATE versus high-dose octreotide LAR in patients with progressive, metastatic midgut NETs, demonstrating exceptional tolerability and efficacy. This review summarizes recent developments in the field of radionuclide therapy for gastroenteropancreatic and lung NETs and considers possible strategies to further enhance its clinical efficacy.

引用

页数：9

共 71 条

[1] Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies [J].

Anthony, LB ;

Woltering, EA ;

Espenan, GD ;

Cronin, MD ;

Maloney, TJ ;

McCarthy, KE .

SEMINARS IN NUCLEAR MEDICINE, 2002, 32 (02) :123-132

[2] The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable [J].

Barber, T. W. ;

Hofman, M. S. ;

Thomson, B. N. J. ;

Hicks, R. J. .

EJSO, 2012, 38 (01) :64-71

[3] Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion:: a phase I study [J].

Bodei, L ;

Cremonesi, M ;

Zoboli, S ;

Grana, C ;

Bartolomei, M ;

Rocca, P ;

Caracciolo, M ;

Mäcke, HR ;

Chinol, M ;

Paganelli, G .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (02) :207-216

[4] Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE:: the role of associated risk factors [J].

Bodei, Lisa ;

Cremonesi, Marta ;

Ferrari, Mahila ;

Pacifici, Monica ;

Grana, Chiara M. ;

Bartolomei, Mirco ;

Baio, Silvia M. ;

Sansovini, Maddalena ;

Paganelli, Giovanni .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (10) :1847-1856

[5] Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer [J].

Bodei, Lisa ;

Kwekkeboom, Dik J. ;

Kidd, Mark ;

Modlin, Irvin M. ;

Krenning, Eric P. .

SEMINARS IN NUCLEAR MEDICINE, 2016, 46 (03) :225-238

[6] Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors [J].

Bodei, Lisa ;

Kidd, Mark ;

Paganelli, Giovanni ;

Grana, Chiara M. ;

Drozdov, Ignat ;

Cremonesi, Marta ;

Lepensky, Christopher ;

Kwekkeboom, Dik J. ;

Baum, Richard P. ;

Krenning, Eric P. ;

Modlin, Irvin M. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (01) :5-19

[7] Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study [J].

Bodei, Lisa ;

Cremonesi, Marta ;

Grana, Chiara M. ;

Fazio, Nicola ;

Iodice, Simona ;

Baio, Silvia M. ;

Bartolomei, Mirco ;

Lombardo, Dario ;

Ferrari, Mahila E. ;

Sansovini, Maddalena ;

Chinol, Marco ;

Paganelli, Giovanni .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (12) :2125-2135

[8] 90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide [J].

Bushnell, David L., Jr. ;

O'Dorisio, Thomas M. ;

O'Dorisio, M. Sue ;

Menda, Yusuf ;

Hicks, Rodney J. ;

Van Cutsem, Eric ;

Baulieu, Jean-Louis ;

Borson-Chazot, Francoise ;

Anthony, Lowell ;

Benson, Al B. ;

Oberg, Kjell ;

Grossman, Ashley B. ;

Connolly, Mary ;

Bouterfa, Hakim ;

Li, Yong ;

Kacena, Katherine A. ;

LaFrance, Norman ;

Pauwels, Stanislas A. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (10) :1652-1659

[9]

Capello A, 2003, J NUCL MED, V44, P98

[10] Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials [J].

Cives, Mauro ;

Soares, Heloisa P. ;

Strosberg, Jonathan .

CURRENT OPINION IN ONCOLOGY, 2016, 28 (04) :359-366

← 1 2 3 4 5 6 7 8 →